Eun-Seok Shin

Interventional cardiologist / Cardiologist
University of Ulsan Hospital -

Latest contributions

DCB: what we know and what we do not know

22 May 2026 – From EuroPCR 2026

This session provides a detailed update on drug-coated balloons (DCB) in interventional cardiology, covering the latest clinical data and trials. It identifies scenarios where DCB use is most effective and offers guidance on optimizing procedural techniques to enhance clinical outcomes.

Typical chest pain: atypical angiogram

20 May 2026 – From EuroPCR 2026

This session addresses the management challenges posed by acute coronary syndromes when angiographic findings are ambiguous or atypical. It highlights the role of intravascular imaging in clarifying diagnoses and discusses recent insights from clinical cases and key studies such as DISCO and the latest NSTEMI EuroIntervention...

DCB and latest DES technology for coronary interventions

22 May 2025 – From EuroPCR 2025

Explore the latest in drug-coated balloon (DCB) and drug-eluting stent (DES) technology for coronary interventions. Review predictors of angiographic outcomes, trial data comparing DCB and DES, and insights into treating calcified lesions and bifurcation disease with novel devices.

DCB and latest DES technology for coronary interventions

Simplify PCI! Know where and how to win with drug-coated balloon

22 May 2025 – From EuroPCR 2025

This session provides a comprehensive update on the use of drug-coated balloons (DCBs) to simplify percutaneous coronary intervention (PCI). It reviews various types of drugs, coatings, and balloon technologies used in DCBs, alongside the latest clinical data supporting their safety and efficacy. It also offers practical insights into...

Simplify PCI! Know where and how to win with drug-coated balloon

DCB-PCI in de novo lesions

20 May 2025 – From EuroPCR 2025

Evaluate the role of drug-coated balloon (DCB) angioplasty in de novo coronary lesions with a focus on vessel diameter effects, comparisons to drug-eluting stents for small non-complex lesions, management of unstented dissections, high bleeding risk scenarios, and optimal dual antiplatelet therapy durations.

DCB-PCI in de novo lesions